Psychedelics and Cannabis

The Psychedelics and Cannabis Working Group was formed in 2023 to explore health (therapeutic and toxicological), regulatory, and social issues related to the broadening decriminalization and clinical use of psychedelic compounds and cannabis, with an emphasis to advocate for scientific input on safety-related issues. Changes to the use and regulation of these compounds, some of which have medicinal histories, raise public and occupational health concerns. The initial discussions of this work group will focus on potential projects to address multidisciplinary concerns for safety, exposure, regulation, and risk. Possible platforms currently in discussion include webinars and sessions at scientific meetings.